Print

Studying the Targeted Therapy Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis

https://www.facingourrisk.org/research-clinical-trials/study/198/studying-the-medication-olaparib-given-with-radium-223-for-advanced-prostate-cancer-with-bone-metastasis

Clinicaltrials.gov identifier:
NCT03317392 (https://clinicaltrials.gov/show/NCT03317392)


People with castration-resistant prostate cancer with bone spread

Study Contact Information:

Contact:  Rana R McKay  858-822-5354 or by email: [email protected]        

About the Study

This study is measuring the best dosage for and side effects of the drug combination Olaparib and radium-223 to treat men with metastatic, castration-resistant prostate cancer that has spread to the bones. 

This study is no longer recruiting patients

Type of Study

 

This is a randomized study with two separate treatment groups.      

Participants are placed into one of two study groups by chance, and neither the participants nor the researchers choose the group into which the participants are placed.

The study allows crossover. Participants in Group 2 whose cancer gets worse will be allowed to switch to Group 1 and receive olaparib.


What the Study Involves


Study Sites

California

Kansas

Maryland

Missouri

New Jersey

Ohio

Pennsylvania

Wisconsin

This Study is Open To:

This study is no longer recruiting patients.

This Study is Not Open To:

This study is no longer recruiting patients.

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.